Patients suffering from dystrophic epidermolysis bullosa are prone to developing autoantibodies against skin proteins: A longitudinal confirmational study
Experimental Dermatology · 2024
DOI: 10.1111/exd.15035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental Dermatology, 2024. Verfasst von J Bremer und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Center for Blistering Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa, Epidermolysis Bullosa, Junctional, Autoimmune Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Fondo Nacional de Desarrollo Científico y Tecnológico, ANID, Chile, Fondo Nacional de Desarrollo Científico y Tecnológico.
Abstract (Originalsprache)
Epidermolysis bullosa (EB) is a heritable skin blistering disease caused by variants in genes coding for proteins that secure cell–cell adhesion and attachment of the epidermis to the dermis. Interestingly, several proteins involved in inherited EB are also associated with autoimmune blistering diseases (AIBD). In this study, we present a long‐term follow‐up of 15 patients suffering from recessive dystrophic or junctional EB. From these patients, 62 sera were analysed for the presence of autoantibodies associated with AIBD. We show that patients suffering from recessive dystrophic EB (RDEB) are more susceptible to developing autoantibodies against skin proteins than patients suffering from junctional EB (70% vs. 20%, respectively). Interestingly, no correlation with age was observed. Most patients showed reactivity to Type XVII collagen/linear IgA bullous dermatosis autoantigen ( n = 5; 33%), followed by BP230 ( n = 4; 27%), Type VII collagen ( n = 4; 27%) and laminin‐332 ( n = 1; 7%). The pathogenicity of these autoantibodies remains a subject for future experiments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Center for Blistering Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
- DEBRA Chile, Santiago, Chile.
- Pediatrics and Pediatric Infectious Diseases of Clínica Alemana, Facultad de Medicina Alemana, Universidad del Desarrollo, Santiago, Chile.
- Servicio de Dermatología, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago, Chile.
- Centro de Genética y Genómica, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago, Chile.
- Departamento de Biología Celular y Molecular, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile.
Förderung
- Fondo Nacional de Desarrollo Científico y Tecnológico, ANID, Chile
- Fondo Nacional de Desarrollo Científico y Tecnológico
Zitieren
APA
Bremer, J., Pas, H. H., Diercks, G. F. H., Meijer, H. J., van der Molen, S. M., Nijenhuis, A. M., van Nijen-Vos, L. L., Morandé, P., Yubero, M. J., Palisson, F., Fuentes, I., & Pasmooij, A. M. G. (2024). Patients suffering from dystrophic epidermolysis bullosa are prone to developing autoantibodies against skin proteins: A longitudinal confirmational study. Experimental Dermatology. https://doi.org/10.1111/exd.15035
Vancouver
Bremer J, Pas HH, Diercks GFH, Meijer HJ, van der Molen SM, Nijenhuis AM, et al. Patients suffering from dystrophic epidermolysis bullosa are prone to developing autoantibodies against skin proteins: A longitudinal confirmational study. Experimental Dermatology. 2024. doi:10.1111/exd.15035
BibTeX
@article{Bremer2024,
author = {Bremer, J and Pas, H H and Diercks, G F H and Meijer, H J and van der Molen, S M and Nijenhuis, A M and van Nijen-Vos, L L and Morandé, P and Yubero, M J and Palisson, F and Fuentes, I and Pasmooij, A M G},
title = {Patients suffering from dystrophic epidermolysis bullosa are prone to developing autoantibodies against skin proteins: A longitudinal confirmational study},
journal = {Experimental Dermatology},
year = {2024},
doi = {10.1111/exd.15035}
}
EUVIMED